Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01059188 | Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 69 | Swiss Cancer InstituteOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT00600015 | Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC) | completed | Phase 2 | 166 | SCRI Development Innovations, LLCOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT00193414 |
| Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer |
| completed |
| Phase 2 |
| 72 |
| SCRI Development Innovations, LLCOTHER |
| 1 |
| Mar 3, 2022 |
| clinicaltrials |
| NCT00193427 | Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 75 | SCRI Development Innovations, LLCOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03798743 | Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS Study(SUCCESS) | completed | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04144582 | Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03794544 | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | completed | Phase 2 | 84 | MedImmune LLCINDUSTRY | 7 | Feb 24, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT03088930 | Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer | completed | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00698815 | Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02044328 | Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation(ICAPE) | completed | Phase 2 | 79 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00043108 | Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT03322566 | A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | completed | Phase 2 | 233 | Incyte CorporationINDUSTRY | 14 | Jan 24, 2022 | clinicaltrials |
| NCT03647488 | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 24, 2022 | clinicaltrials |
| NCT02318277 | A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203) | completed | Phase 1 / Phase 2 | 176 | Incyte CorporationINDUSTRY | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01248247 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 334 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03659578 | Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer | completed | Phase 2 | 69 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT00741988 | Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | completed | Phase 2 | 82 | SCRI Development Innovations, LLCOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02936323 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | completed | Phase 1 / Phase 2 | 89 | Tarveda TherapeuticsINDUSTRY | 2 | Dec 14, 2021 | clinicaltrials |
| NCT00695292 | Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT03371979 | Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 68 | Aeglea BiotherapeuticsINDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT01757288 | Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC | completed | Phase 1 / Phase 2 | 98 | University of Texas Southwestern Medical CenterOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01951586 | Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 226 | AmgenINDUSTRY | 10 | Oct 25, 2021 | clinicaltrials |
| NCT03574753 | Lung-MAP S1400K: c-MET Positive | completed | Phase 2 | 28 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 18, 2021 | clinicaltrials |
| NCT01905657 | Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | completed | Phase 2 / Phase 3 | 1,034 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 6, 2021 | clinicaltrials |
| NCT02303977 | Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | completed | Phase 2 | 37 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT01535040 | Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking | completed | Phase 2 | 130 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT03261947 | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | completed | Phase 2 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 20, 2021 | clinicaltrials |
| NCT00871923 | Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT00025272 | Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00025285 | Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 46 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT00004202 | Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | — | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Aug 26, 2021 | clinicaltrials |
| NCT01449461 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) | completed | Phase 1 / Phase 2 | 137 | Ariad PharmaceuticalsINDUSTRY | 0 | Aug 17, 2021 | clinicaltrials |
| NCT02450539 | A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer | completed | Phase 2 | 159 | Eli Lilly and CompanyINDUSTRY | 13 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02531737 | Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer(REFRACT) | completed | Phase 2 | 59 | University Hospital, LimogesOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT02498860 | Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung(APICAL) | completed | Phase 2 | 106 | Chonnam National University HospitalOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT02629523 | Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA(LiquidLung-A) | completed | Phase 2 | 21 | Chonnam National University HospitalOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02769286 | Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA(LiquidLung-O) | completed | Phase 2 | 38 | Chonnam National University HospitalOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02674568 | Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer(TRINITY) | completed | Phase 2 | 342 | AbbVieINDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT01620190 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 26 | University of WashingtonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT02879994 | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 11 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT03377556 | Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | completed | Phase 2 | 51 | SWOG Cancer Research NetworkNETWORK | 2 | Jun 23, 2021 | clinicaltrials |
| NCT02701400 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 18 | Emory UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2022source: clinicaltrials